Aardvark Therapeutics reports FY2025 net loss $57.6M; pauses all clinical trials after cardiac signal

Aardvark Therapeutics, Inc.

Net loss $57.6M for FY2025 vs $20.6M in FY2024; cash $110.0M supports operations into Q2 2027.
Voluntary pause of Phase 3 HERO and OLE trials for ARD-101 in PWS after reversible QRS prolongation in healthy volunteers.
ARD-201 obesity trials (POWER, STRENGTH) also voluntarily paused; further guidance expected Q2 2026.
Clinical and preclinical data published in Molecular Metabolism showing ARD-101 reduced hunger and increased gut hormones.
R&D spend $48.9M in FY2025 up from $17.4M; G&A $13.8M up from $5.3M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Aardvark Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 23, 2026, Aardvark Therapeutics, Inc. issued a press release reporting its financial results for the quarter and full year ended December 31, 2025, and providing pipeline and business updates.

View on SEC.gov

Browse all earnings releases →

Aardvark Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-119727

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.